Ojemda
Ojemda ingredients
| Active ingredient | Strength |
|---|---|
| Tovorafenib | 100 mg/1 |
What Ojemda is used for
The FDA lists the approved uses on the official label (below). In the EU, tovorafenib is approved as Ojemda for:
Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ojemda
- Generic name
- Tovorafenib
- Made by
- Day One Biopharmaceuticals, Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA217700
- On the US market since
- 2024
Official information
- Ojemda prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tovorafenib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ojemda?
Ojemda (Tovorafenib) is a cancer medicine made by Day One Biopharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Ojemda?
Ojemda contains Tovorafenib (100 mg/1).
Is Ojemda approved in Europe?
The same active substance is approved in the EU as Ojemda.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA